

Appl. No. 09/488,728  
Amdt. and Reply dated August 4, 2005  
Resp. to OA, dated February 24, 2005

### 3. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-12 (*Cancelled*)

13. (*Previously presented*) A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:

- (a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
- (b) a protein comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) that binds IL-17; and
- (c) a fragment of (a) that binds IL-17.

14-16 (*Cancelled*)

17. (*Previously presented*) A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:

- (a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
- (b) a protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) that binds IL-17; and
- (c) a fragment of (a) that binds IL-17.

18. (*Cancelled*)

19. (*Previously presented*) A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.

20. (*Previously presented*) A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier,

Appl. No. 09/488,728  
Amdt. and Reply dated August 4, 2005  
Resp. to OA, dated February 24, 2005

wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.

21. *(Previously presented)* A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.

22. *(Previously presented)* The method according to claim 13, wherein the soluble IL-17R protein further comprises an Fc domain.

23. *(Previously presented)* The method according to claim 13, wherein the soluble IL-17R protein further comprises an oligomerizing domain.

24. *(Previously presented)* A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.

25. *(Previously presented)* A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.

26. *(Previously presented)* A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.

27. *(Previously presented)* The method according to claim 17, wherein the soluble IL-17R protein further comprises an Fc domain.

Appl. No. 09/488,728  
Amdt. and Reply dated August 4, 2005  
Resp. to OA, dated February 24, 2005

28. *(Previously presented)* The method according to claim 17, wherein the soluble IL-17R protein further comprises an oligomerizing domain.